BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Small Cell Lung Cancer readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Small Cell Lung Cance
 r\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05856695-1959@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05856695)
DESCRIPTION:Durvalumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Durvalum
 ab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-d
 isease Small-sell Lung Cancer (SCLC)\nEstimated primary completion: Novemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05856
 695
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06501976-2601@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lurbinectedin: Phase 2 readout est. (NCT06501976)
DESCRIPTION:Lurbinectedin\, phase 2\, Small Cell Lung Cancer.\nStudy: An Ex
 ploratory Study of Lurbinectedin With Radiotherapy in SCLC With Single-les
 ion Progression After First Course Treatment\nEstimated primary completion
 : December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lurb
 inectedin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06501976
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06497530-2161@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Serplulimab: Phase 2 readout est. (NCT06497530)
DESCRIPTION:Serplulimab\, phase 2\, Small Cell Lung Cancer.\nStudy: Mainten
 ance Lurbinectedin in Combination With Serplulimab for Patients With ES-SC
 LC\nEstimated primary completion: December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06497530
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06497530-2601@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lurbinectedin: Phase 2 readout est. (NCT06497530)
DESCRIPTION:Lurbinectedin\, phase 2\, Small Cell Lung Cancer.\nStudy: Maint
 enance Lurbinectedin in Combination With Serplulimab for Patients With ES-
 SCLC\nEstimated primary completion: December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/lurbinectedin#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06497530
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06483282-2166@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06483282)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Study
  of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoad
 juvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Can
 cer\nEstimated primary completion: 1 December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06483282
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06771518-1962@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT06771518)
DESCRIPTION:Atezolizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Associ
 ation of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy T
 reatment With Atezolizumab\nEstimated primary completion: 15 December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06771518
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05578326-2601@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261225
DTEND;VALUE=DATE:20261226
SUMMARY:Lurbinectedin: Phase 2 readout est. (NCT05578326)
DESCRIPTION:Lurbinectedin\, phase 2\, Small Cell Lung Cancer.\nStudy: Study
  of Trilaciclib and Lurbinectidin\nEstimated primary completion: 25 Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/lurbinectedi
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 578326
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07141264-2166@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07141264)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: Adebrel
 imab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy\nEstim
 ated primary completion: 30 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07141264
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04602533-1959@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04602533)
DESCRIPTION:Durvalumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Efficacy
  and Safety of Standard of Care Plus Durvalumab in Patients With Limited D
 isease Small Cell Lung Cancer (DOLPHIN)\nEstimated primary completion: 31 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durval
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04602533
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06536868-2010@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06536868)
DESCRIPTION:Tislelizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Tislel
 izumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC\nEs
 timated primary completion: 31 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06536868
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07208773-2817@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Tambotatug pelitecan: Phase 1/2 readout est. (NCT07208773)
DESCRIPTION:Tambotatug pelitecan\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors\
 nEstimated primary completion: January 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07208773
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04699838-1959@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04699838)
DESCRIPTION:Durvalumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Chemo-Im
 munotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Pa
 tients With Extensive Stage Small Cell Lung Cancer\nEstimated primary comp
 letion: January 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT04699838
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06793228-2010@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06793228)
DESCRIPTION:Tislelizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Nanocr
 ystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia\nEstima
 ted primary completion: 15 January 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06793228
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06295926-2161@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270125
DTEND;VALUE=DATE:20270126
SUMMARY:Serplulimab: Phase 2 readout est. (NCT06295926)
DESCRIPTION:Serplulimab\, phase 2\, Small Cell Lung Cancer.\nStudy: Serplul
 imab Combined With CCRT for LS-SCLC.\nEstimated primary completion: 25 Jan
 uary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/serplulima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 295926
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06851819-2010@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06851819)
DESCRIPTION:Tislelizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Tislel
 izumab in Combination with Chemotherapy ± Radiotherapy for Extensive-Stag
 e Oligometastatic Small Cell Lung Cancer.\nEstimated primary completion: 3
 1 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tisle
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06851819
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06223711-1959@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06223711)
DESCRIPTION:Durvalumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Durvalum
 ab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiothe
 rapy in Oligometastatic ES-SCLC\nEstimated primary completion: March 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06223711
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06838208-2010@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06838208)
DESCRIPTION:Tislelizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Tislel
 izumab Combined With Chemotherapy and Relayed Radiotherapy in First-line T
 reatment of ES-SCLC\nEstimated primary completion: 1 March 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06838208
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06306560-2166@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270315
DTEND;VALUE=DATE:20270316
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06306560)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Study
  of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment 
 of ES-SCLC.\nEstimated primary completion: 15 March 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06306560
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06830694-1962@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT06830694)
DESCRIPTION:Atezolizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Clinic
 al Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) Wi
 th Etoposide\, Carboplatin and Atezolizumab in Transformed Small Cell Lung
  Cancer Patients From Adenocarcinoma After EGFR TKI Treatment\nEstimated p
 rimary completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06830694
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06830694-2753@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Tarlatamab: Phase 2 readout est. (NCT06830694)
DESCRIPTION:Tarlatamab\, phase 2\, Small Cell Lung Cancer.\nStudy: Clinical
  Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With
  Etoposide\, Carboplatin and Atezolizumab in Transformed Small Cell Lung C
 ancer Patients From Adenocarcinoma After EGFR TKI Treatment\nEstimated pri
 mary completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/tarlatamab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06830694
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07640932-2601@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Lurbinectedin: Phase 2 readout est. (NCT07640932)
DESCRIPTION:Lurbinectedin\, phase 2\, Small Cell Lung Cancer.\nStudy: Lurbi
 nectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Tre
 ated Small Cell Lung Cancer\nEstimated primary completion: April 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/lurbinectedin#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07640932
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06332950-2166@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT06332950)
DESCRIPTION:Adebrelimab\, phase 1/2\, Small Cell Lung Cancer.\nStudy: Safet
 y and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Withou
 t Famitinib in ES-SCLC Pre-treated With Immunotherapy\nEstimated primary c
 ompletion: 1 April 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/adebrelimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06332950
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06375109-2010@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270415
DTEND;VALUE=DATE:20270416
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06375109)
DESCRIPTION:Tislelizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: PD-L1/
 PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadj
 uvant Treatment of Limited-stage SCLC\nEstimated primary completion: 15 Ap
 ril 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 375109
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06943235-2166@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06943235)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: Study o
 f Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy 
 and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small 
 Cell Lung Cancer (LS-SCLC)\nEstimated primary completion: 30 April 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06943235
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06616532-1990@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pumitamig: Phase 3 readout est. (NCT06616532)
DESCRIPTION:Pumitamig\, phase 3\, Small Cell Lung Cancer.\nStudy: PM8002 in
  Combination With Paclitaxel Compared With Chemotherapy as Second-line Tre
 atment in Small Cell Lung Cancer\nEstimated primary completion: May 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pumitamig#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06616532
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07583511-2161@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07583511)
DESCRIPTION:Serplulimab\, phase 2\, Small Cell Lung Cancer.\nStudy: Tenipos
 ide\, Cisplatin and Serplulimab for Treatment of ES-SCLC\, a Randomized Co
 ntrolled Study\nEstimated primary completion: 1 May 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07583511
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07016230-2753@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270518
DTEND;VALUE=DATE:20270519
SUMMARY:Tarlatamab: Phase 2 readout est. (NCT07016230)
DESCRIPTION:Tarlatamab\, phase 2\, Small Cell Lung Cancer.\nStudy: Study In
 vestigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advan
 ced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroend
 ocrine Carcinomas (NECs)\, With Biomarker Analysis to Characterize Respons
 e/Resistance (UNLOCK TARLATAMAB)\nEstimated primary completion: 18 May 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/tarlatamab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07016230
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06449209-1990@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pumitamig: Phase 2 readout est. (NCT06449209)
DESCRIPTION:Pumitamig\, phase 2\, Small Cell Lung Cancer.\nStudy: Safety\, 
 Preliminary Effectiveness of BNT327\, an Investigational Therapy for Patie
 nts With Small-cell Lung Cancer in Combination With Chemotherapy\nEstimate
 d primary completion: June 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pumitamig#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06449209
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07253142-2161@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270618
DTEND;VALUE=DATE:20270619
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07253142)
DESCRIPTION:Serplulimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab i
 n Subjects With Advanced Lung Cancer\nEstimated primary completion: 18 Jun
 e 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07253
 142
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04696575-1962@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04696575)
DESCRIPTION:Atezolizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Lamivu
 dine in Combination With Chemoimmunotherapy for the Treatment of Extensive
  Stage Small Cell Lung Cancer\nEstimated primary completion: 1 July 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04696575
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06362252-1962@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270720
DTEND;VALUE=DATE:20270721
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT06362252)
DESCRIPTION:Atezolizumab\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A St
 udy of I-DXd in Combination With Atezolizumab With or Without Carboplatin 
 as First-Line Induction or Maintenance in Subjects With Extensive Stage-Sm
 all Cell Lung Cancer (IDeate-Lung03)\nEstimated primary completion: 20 Jul
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0636
 2252
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06362252-2527@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270720
DTEND;VALUE=DATE:20270721
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT06362252)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2\, Small Cell Lung Cancer.\nSt
 udy: A Study of I-DXd in Combination With Atezolizumab With or Without Car
 boplatin as First-Line Induction or Maintenance in Subjects With Extensive
  Stage-Small Cell Lung Cancer (IDeate-Lung03)\nEstimated primary completio
 n: 20 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ifin
 atamab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06362252
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06786312-2166@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270725
DTEND;VALUE=DATE:20270726
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06786312)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Singl
 e-arm\, Multicenter\, Prospective Phase II Clinical Study of Apatinib in C
 ombination With Adebrelimab and EC Regimen in the First-line Treatment of 
 Extensive Small Cell Lung Cancer\nEstimated primary completion: 25 July 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06786312
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07803848-2753@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270729
DTEND;VALUE=DATE:20270730
SUMMARY:Tarlatamab: Phase 2 readout est. (NCT07803848)
DESCRIPTION:Tarlatamab\, phase 2\, Small Cell Lung Cancer.\nStudy: Study to
  Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With
  Extensive Stage Small-cell Lung Cancer With Poor Performance Status\nEsti
 mated primary completion: 29 July 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tarlatamab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07803848
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06562920-2166@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06562920)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: Adebrel
 imab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatm
 ent of Limited-stage Small Cell Lung Cancer\nEstimated primary completion:
  31 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/adebre
 limab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06562920
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05496166-2166@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Adebrelimab: Phase 3 readout est. (NCT05496166)
DESCRIPTION:Adebrelimab\, phase 3\, Small Cell Lung Cancer.\nStudy: The Eff
 iciency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Plati
 num-containing Doublet Induction Therapy for Limited-stage Small Cell Lung
  Cancer\nEstimated primary completion: 1 August 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05496166
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06646276-11178@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270817
DTEND;VALUE=DATE:20270818
SUMMARY:Atigotatug: Phase 3 readout est. (NCT06646276)
DESCRIPTION:Atigotatug\, phase 3\, Small Cell Lung Cancer.\nStudy: A Study 
 to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fi
 xed Dose Combination) in Combination With Carboplatin Plus Etoposide to Th
 at of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy i
 n Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).\nEstim
 ated primary completion: 17 August 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/atigotatug#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06646276
URL:https://assetmemo.bio/drug/atigotatug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07909863-2166@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07909863)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: Low-Dos
 e Radiotherapy Plus Adebrelimab and Chemotherapy for Extensive-Stage Small
  Cell Lung Cancer\nEstimated primary completion: 1 September 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07909863
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07778316-2753@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:Tarlatamab: Phase 3 readout est. (NCT07778316)
DESCRIPTION:Tarlatamab\, phase 3\, Small Cell Lung Cancer.\nStudy: Phase 3 
 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer A
 fter Platinum Based First-line Chemotherapy (ES-SCLC)\nEstimated primary c
 ompletion: 24 September 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/tarlatamab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07778316
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04397003-1959@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04397003)
DESCRIPTION:Durvalumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Personal
 ized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Exten
 sive Stage Small Cell Lung Cancer\nEstimated primary completion: 30 Septem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0439
 7003
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05796089-1959@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05796089)
DESCRIPTION:Durvalumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Chemothe
 rapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thor
 acic Radiotherapy\nEstimated primary completion: 30 September 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05796089
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05068232-1959@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05068232)
DESCRIPTION:Durvalumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Durvalum
 ab and Ablative Radiation in Small Cell Lung Cancer (DARES)\nEstimated pri
 mary completion: 1 October 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05068232
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07583550-2166@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07583550)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: Low-dos
 e Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy\, and Th
 en Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Sma
 ll Cell Lung Cancer\nEstimated primary completion: 30 October 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07583550
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06095505-3378@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Alisertib: Phase 2 readout est. (NCT06095505)
DESCRIPTION:Alisertib\, phase 2\, Small Cell Lung Cancer.\nStudy: A Study o
 f Alisertib in Patients With Extensive Stage Small Cell Lung Cancer\nEstim
 ated primary completion: 30 October 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/alisertib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06095505
URL:https://assetmemo.bio/drug/alisertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07099898-2501@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271105
DTEND;VALUE=DATE:20271106
SUMMARY:Risvutatug rezetecan: Phase 3 readout est. (NCT07099898)
DESCRIPTION:Risvutatug rezetecan\, phase 3\, Small Cell Lung Cancer.\nStudy
 : A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Canc
 er (SCLC) [EMBOLD SCLC-301]\nEstimated primary completion: 5 November 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/risvutatug-rezeteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 099898
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06526624-2501@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Risvutatug rezetecan: Phase 3 readout est. (NCT06526624)
DESCRIPTION:Risvutatug rezetecan\, phase 3\, Small Cell Lung Cancer.\nStudy
 : A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell L
 ung Cancer\nEstimated primary completion: 30 November 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06526624
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05652686-1962@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT05652686)
DESCRIPTION:Atezolizumab\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A St
 udy of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expre
 ssing DLL3 (the SKYBRIDGE Study)\nEstimated primary completion: December 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0565268
 6
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05703971-1962@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT05703971)
DESCRIPTION:Atezolizumab\, phase 1/2\, Small Cell Lung Cancer.\nStudy: Quar
 atusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-
 SCLC Patients\nEstimated primary completion: December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05703971
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05703971-2205@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Reqorsa (Quaratusugene Ozeplasmid): Phase 1/2 readout est. (NCT0570
 3971)
DESCRIPTION:Reqorsa (Quaratusugene Ozeplasmid)\, phase 1/2\, Small Cell Lun
 g Cancer.\nStudy: Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Main
 tenance Therapy in ES-SCLC Patients\nEstimated primary completion: Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/quaratusugene
 -ozeplasmid#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05703971
URL:https://assetmemo.bio/drug/quaratusugene-ozeplasmid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05652686-2601@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lurbinectedin: Phase 1/2 readout est. (NCT05652686)
DESCRIPTION:Lurbinectedin\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A S
 tudy of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expr
 essing DLL3 (the SKYBRIDGE Study)\nEstimated primary completion: December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/lurbinectedin#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05652
 686
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04472949-1959@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04472949)
DESCRIPTION:Durvalumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Thoracic
  Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and
  Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Canc
 er (ED-SCLC).\nEstimated primary completion: December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04472949
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07654400-1962@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07654400)
DESCRIPTION:Atezolizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Stud
 y of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-
 stage Small Cell Lung Cancer\nEstimated primary completion: December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07654400
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05363280-2275@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:AL8326: Phase 2 readout est. (NCT05363280)
DESCRIPTION:AL8326\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Phase 2 
 Study for the Patient\, Who Has Diagnosed With Small Cell Lung Cancer (SCL
 C) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and
  Finished the First Line Stand Treatment \, Need More Treatment\nEstimated
  primary completion: December 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/al8326#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05363280
URL:https://assetmemo.bio/drug/al8326#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06614621-2166@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06614621)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Study
  of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequen
 tial Treatment for Extensive-stage Small Cell Lung Cancer\nEstimated prima
 ry completion: 1 December 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06614621
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06612151-2817@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Tambotatug pelitecan: Phase 3 readout est. (NCT06612151)
DESCRIPTION:Tambotatug pelitecan\, phase 3\, Small Cell Lung Cancer.\nStudy
 : A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (TAISHAN-3
 02)\nEstimated primary completion: 1 December 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06612151
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05882058-7739@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271217
DTEND;VALUE=DATE:20271218
SUMMARY:Obrixtamig: Phase 2 readout est. (NCT05882058)
DESCRIPTION:Obrixtamig\, phase 2\, Small Cell Lung Cancer.\nStudy: DAREON
 ™-5: A Study to Test Whether Different Doses of BI 764532 Help People Wi
 th Small Cell Lung Cancer or Other Neuroendocrine Cancers\nEstimated prima
 ry completion: 17 December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/obrixtamig#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05882058
URL:https://assetmemo.bio/drug/obrixtamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05060016-2753@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Tarlatamab: Phase 2 readout est. (NCT05060016)
DESCRIPTION:Tarlatamab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Phase 
 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)\nEsti
 mated primary completion: 30 December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/tarlatamab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05060016
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04919382-1962@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04919382)
DESCRIPTION:Atezolizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Temozo
 lomide and Atezolizumab for Subsequent Line for the Treatment of Metastati
 c or Recurrent Small Cell Lung Cancer\nEstimated primary completion: 30 De
 cember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezoliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04919382
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04728230-1959@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT04728230)
DESCRIPTION:Durvalumab\, phase 1/2\, Small Cell Lung Cancer.\nStudy: Olapar
 ib and Durvalumab With Carboplatin\, Etoposide\, and/or Radiation Therapy 
 for the Treatment of Extensive-Stage Small Cell Lung Cancer\, PRIO Trial\n
 Estimated primary completion: 31 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04728230
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07425795-2010@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07425795)
DESCRIPTION:Tislelizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Tislel
 izumab Combined With Chemotherapy Followed by Thoracic Consolidation Radio
 therapy in the First-line Treatment of Extensive Stage Small Cell Lung Can
 cer\nEstimated primary completion: 31 December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07425795
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07423585-2753@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tarlatamab: Phase 2 readout est. (NCT07423585)
DESCRIPTION:Tarlatamab\, phase 2\, Small Cell Lung Cancer.\nStudy: Tarlatam
 ab for the Treatment of Extensive Stage Small-cell Lung Cancer\nEstimated 
 primary completion: 31 December 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/tarlatamab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07423585
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06496048-2601@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lurbinectedin: Phase 3 readout est. (NCT06496048)
DESCRIPTION:Lurbinectedin\, phase 3\, Small Cell Lung Cancer.\nStudy: Lurbi
 nectedin or in Combination with Irinotecan Versus Topotecan in Patients wi
 th Relapsed SCLC\nEstimated primary completion: 31 December 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/lurbinectedin#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06496048
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04471727-1962@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280128
DTEND;VALUE=DATE:20280129
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT04471727)
DESCRIPTION:Atezolizumab\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A St
 udy in Participants With Advanced Cancers Associated With Expression of DL
 L3 (MK-6070-001/HPN328-4001)\nEstimated primary completion: 28 January 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04471727
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04471727-2527@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280128
DTEND;VALUE=DATE:20280129
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT04471727)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2\, Small Cell Lung Cancer.\nSt
 udy: A Study in Participants With Advanced Cancers Associated With Express
 ion of DLL3 (MK-6070-001/HPN328-4001)\nEstimated primary completion: 28 Ja
 nuary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ifinatama
 b-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT04471727
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04471727-11236@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280128
DTEND;VALUE=DATE:20280129
SUMMARY:Gocatamig: Phase 1/2 readout est. (NCT04471727)
DESCRIPTION:Gocatamig\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A Study
  in Participants With Advanced Cancers Associated With Expression of DLL3 
 (MK-6070-001/HPN328-4001)\nEstimated primary completion: 28 January 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/gocatamig#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04471727
URL:https://assetmemo.bio/drug/gocatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06203210-2527@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Ifinatamab Deruxtecan: Phase 3 readout est. (NCT06203210)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 3\, Small Cell Lung Cancer.\nStud
 y: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice
  in Subjects With Relapsed Small Cell Lung Cancer\nEstimated primary compl
 etion: 30 January 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/ifinatamab-deruxtecan#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06203210
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07398560-2166@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07398560)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: Adebrel
 imab Combined With Oral Etoposide for Elderly Patients and Patients With P
 oor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical 
 Study\nEstimated primary completion: 1 February 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07398560
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05617963-1959@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280224
DTEND;VALUE=DATE:20280225
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05617963)
DESCRIPTION:Durvalumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Durvalum
 ab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung C
 ancer Patients Whose Disease is Limited to the Thorax\nEstimated primary c
 ompletion: 24 February 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05617963
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05142696-1962@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280307
DTEND;VALUE=DATE:20280308
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT05142696)
DESCRIPTION:Atezolizumab\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A St
 udy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combinat
 ion With Carboplatin\, Etoposide and Atezolizumab\nEstimated primary compl
 etion: 7 March 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 atezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05142696
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07200154-2166@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07200154)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: Adebrel
 imab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited
 -Stage SCLC\nEstimated primary completion: 30 March 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07200154
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07109401-2010@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07109401)
DESCRIPTION:Tislelizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Periop
 erative Immunotherapy for Resectable Limited-Stage SCLC\nEstimated primary
  completion: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/tislelizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07109401
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07465757-3378@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Alisertib: Phase 2 readout est. (NCT07465757)
DESCRIPTION:Alisertib\, phase 2\, Small Cell Lung Cancer.\nStudy: A Study o
 f Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)\
 nEstimated primary completion: 31 March 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/alisertib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07465757
URL:https://assetmemo.bio/drug/alisertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06247605-2275@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:AL8326: Phase 3 readout est. (NCT06247605)
DESCRIPTION:AL8326\, phase 3\, Small Cell Lung Cancer.\nStudy: A Phase IIII
  Study of AL8326 in Small Cell Lung Cancer\nEstimated primary completion: 
 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/al8326#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0624760
 5
URL:https://assetmemo.bio/drug/al8326#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07381543-2166@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07381543)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: Adebrel
 imab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus
  CRT or CRT Alone\nEstimated primary completion: August 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07381543
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06773156-2166@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06773156)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: Adjuvan
 t Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Ce
 ll Lung Cancer\nEstimated primary completion: 1 August 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06773156
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05800587-2601@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Lurbinectedin: Phase 2 readout est. (NCT05800587)
DESCRIPTION:Lurbinectedin\, phase 2\, Small Cell Lung Cancer.\nStudy: Dose 
 Attenuated Chemotherapy in Compromised Patients With Lung Cancer\nEstimate
 d primary completion: 1 August 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/lurbinectedin#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05800587
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06663098-1962@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280830
DTEND;VALUE=DATE:20280831
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT06663098)
DESCRIPTION:Atezolizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Atezol
 izumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-st
 age Small Cell Lung Cancer (ES-SCLC).\nEstimated primary completion: 30 Au
 gust 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6663098
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07472517-1962@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280909
DTEND;VALUE=DATE:20280910
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT07472517)
DESCRIPTION:Atezolizumab\, phase 3\, Small Cell Lung Cancer.\nStudy: DAREON
  ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Com
 pare Obrixtamig Plus Atezolizumab\, Carboplatin\, and Etoposide Treatment 
 With Standard Chemoimmunotherapy\nEstimated primary completion: 9 Septembe
 r 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0747
 2517
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07472517-7739@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280909
DTEND;VALUE=DATE:20280910
SUMMARY:Obrixtamig: Phase 3 readout est. (NCT07472517)
DESCRIPTION:Obrixtamig\, phase 3\, Small Cell Lung Cancer.\nStudy: DAREON 
 ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Comp
 are Obrixtamig Plus Atezolizumab\, Carboplatin\, and Etoposide Treatment W
 ith Standard Chemoimmunotherapy\nEstimated primary completion: 9 September
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/obrixtamig#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0747251
 7
URL:https://assetmemo.bio/drug/obrixtamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07357532-2166@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280926
DTEND;VALUE=DATE:20280927
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07357532)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: Explora
 tion of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCL
 C Guided by MRD\nEstimated primary completion: 26 September 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07357532
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407933-1962@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT07407933)
DESCRIPTION:Atezolizumab\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A St
 udy of YL201 in Combination With Other Anti-Cancer Therapies in Patients W
 ith Advanced Solid Tumors\nEstimated primary completion: November 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07407933
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407933-2817@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Tambotatug pelitecan: Phase 1/2 readout est. (NCT07407933)
DESCRIPTION:Tambotatug pelitecan\, phase 1/2\, Small Cell Lung Cancer.\nStu
 dy: A Study of YL201 in Combination With Other Anti-Cancer Therapies in Pa
 tients With Advanced Solid Tumors\nEstimated primary completion: November 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/tambotatug-peli
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07407933
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07798947-2166@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07798947)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Phase
  II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection 
 in Patients With LS-SCLC\nEstimated primary completion: December 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07798947
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06769126-1959@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06769126)
DESCRIPTION:Durvalumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Using Bi
 omarker Tests to Select and Test New\, Personalized Treatments for Extensi
 ve Stage Small Cell Lung Cancer\, PRISM Study\nEstimated primary completio
 n: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06769126
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07815223-2010@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07815223)
DESCRIPTION:Tislelizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Phas
 e II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradioth
 erapy in LS-SCLC\nEstimated primary completion: 31 December 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07815223
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07005128-1959@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290104
DTEND;VALUE=DATE:20290105
SUMMARY:Durvalumab: Phase 3 readout est. (NCT07005128)
DESCRIPTION:Durvalumab\, phase 3\, Small Cell Lung Cancer.\nStudy: A Study 
 Comparing Tarlatamab\, Durvalumab\, Carboplatin\, and Etoposide Versus Dur
 valumab\, Carboplatin\, and Etoposide in First-line Extensive Stage Small-
 Cell Lung Cancer (ES-SCLC)\nEstimated primary completion: 4 January 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07005128
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07005128-2753@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290104
DTEND;VALUE=DATE:20290105
SUMMARY:Tarlatamab: Phase 3 readout est. (NCT07005128)
DESCRIPTION:Tarlatamab\, phase 3\, Small Cell Lung Cancer.\nStudy: A Study 
 Comparing Tarlatamab\, Durvalumab\, Carboplatin\, and Etoposide Versus Dur
 valumab\, Carboplatin\, and Etoposide in First-line Extensive Stage Small-
 Cell Lung Cancer (ES-SCLC)\nEstimated primary completion: 4 January 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/tarlatamab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07005128
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07149363-1959@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07149363)
DESCRIPTION:Durvalumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Adjuvant
  Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Ca
 ncer\nEstimated primary completion: February 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07149363
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07402343-2753@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Tarlatamab: Phase 2 readout est. (NCT07402343)
DESCRIPTION:Tarlatamab\, phase 2\, Small Cell Lung Cancer.\nStudy: Tarlatam
 ab for SCLC Brain Metastases\nEstimated primary completion: February 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/tarlatamab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07402343
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07339059-1959@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07339059)
DESCRIPTION:Durvalumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Study of
  Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy
  for Extensive-Stage Small Cell Lung Cancer\nEstimated primary completion:
  1 February 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dur
 valumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07339059
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07339059-1962@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07339059)
DESCRIPTION:Atezolizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Study 
 of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Thera
 py for Extensive-Stage Small Cell Lung Cancer\nEstimated primary completio
 n: 1 February 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 tezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07339059
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780137-1959@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290215
DTEND;VALUE=DATE:20290216
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT06780137)
DESCRIPTION:Durvalumab\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A Stud
 y to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatama
 b Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-St
 age Small Cell Lung Cancer (MK-6070-002)\nEstimated primary completion: 15
  February 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durva
 lumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06780137
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780137-2527@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290215
DTEND;VALUE=DATE:20290216
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT06780137)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2\, Small Cell Lung Cancer.\nSt
 udy: A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) an
 d Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory E
 xtensive-Stage Small Cell Lung Cancer (MK-6070-002)\nEstimated primary com
 pletion: 15 February 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ifinatamab-deruxtecan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06780137
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780137-11236@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290215
DTEND;VALUE=DATE:20290216
SUMMARY:Gocatamig: Phase 1/2 readout est. (NCT06780137)
DESCRIPTION:Gocatamig\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A Study
  to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab
  Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Sta
 ge Small Cell Lung Cancer (MK-6070-002)\nEstimated primary completion: 15 
 February 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gocata
 mig#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06780137
URL:https://assetmemo.bio/drug/gocatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07153055-2601@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Lurbinectedin: Phase 1/2 readout est. (NCT07153055)
DESCRIPTION:Lurbinectedin\, phase 1/2\, Small Cell Lung Cancer.\nStudy: Lur
 binectedin With Osimertinib in Transformed Small Cell Lung Cancer\nEstimat
 ed primary completion: April 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/lurbinectedin#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07153055
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07155174-1962@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07155174)
DESCRIPTION:Atezolizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Stud
 y to Evaluate the Optimal Dose\, Adverse Events and Change in Disease Acti
 vity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Stand
 ard of Care as First-Line Treatment in Adult Participants With Previously 
 Untreated Extensive Stage Small Cell Lung Cancer\nEstimated primary comple
 tion: April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ate
 zolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07155174
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07155174-2601@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Lurbinectedin: Phase 2 readout est. (NCT07155174)
DESCRIPTION:Lurbinectedin\, phase 2\, Small Cell Lung Cancer.\nStudy: A Stu
 dy to Evaluate the Optimal Dose\, Adverse Events and Change in Disease Act
 ivity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Stan
 dard of Care as First-Line Treatment in Adult Participants With Previously
  Untreated Extensive Stage Small Cell Lung Cancer\nEstimated primary compl
 etion: April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lu
 rbinectedin#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07155174
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07155174-11131@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:ABBV-706: Phase 2 readout est. (NCT07155174)
DESCRIPTION:ABBV-706\, phase 2\, Small Cell Lung Cancer.\nStudy: A Study to
  Evaluate the Optimal Dose\, Adverse Events and Change in Disease Activity
  of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard 
 of Care as First-Line Treatment in Adult Participants With Previously Untr
 eated Extensive Stage Small Cell Lung Cancer\nEstimated primary completion
 : April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abbv-70
 6#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 155174
URL:https://assetmemo.bio/drug/abbv-706#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06712355-1990@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Pumitamig: Phase 3 readout est. (NCT06712355)
DESCRIPTION:Pumitamig\, phase 3\, Small Cell Lung Cancer.\nStudy: Safety an
 d Efficacy of BNT327\, an Investigational Therapy in Combination With Chem
 otherapy for Patients With Untreated Small-cell Lung Cancer\nEstimated pri
 mary completion: April 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/pumitamig#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06712355
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07325136-1990@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290423
DTEND;VALUE=DATE:20290424
SUMMARY:Pumitamig: Phase 1/2 readout est. (NCT07325136)
DESCRIPTION:Pumitamig\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A Study
  to Assess the Safety and Tolerability of BMS-986525 Alone and in Combinat
 ion Therapy in Participants With Relapsed/Refractory Small Cell Lung Cance
 r\nEstimated primary completion: 23 April 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pumitamig#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07325136
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07325136-11180@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290423
DTEND;VALUE=DATE:20290424
SUMMARY:BMS-986525: Phase 1/2 readout est. (NCT07325136)
DESCRIPTION:BMS-986525\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A Stud
 y to Assess the Safety and Tolerability of BMS-986525 Alone and in Combina
 tion Therapy in Participants With Relapsed/Refractory Small Cell Lung Canc
 er\nEstimated primary completion: 23 April 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/bms-986525#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07325136
URL:https://assetmemo.bio/drug/bms-986525#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07739758-2161@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Serplulimab: Phase 3 readout est. (NCT07739758)
DESCRIPTION:Serplulimab\, phase 3\, Small Cell Lung Cancer.\nStudy: A Study
  of YL201 in Combination With Serplulimab in Participants With Treatment-n
 aïve Extensive-stage Small Cell Lung Cancer\nEstimated primary completion
 : June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/serpluli
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07739758
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07739758-2817@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Tambotatug pelitecan: Phase 3 readout est. (NCT07739758)
DESCRIPTION:Tambotatug pelitecan\, phase 3\, Small Cell Lung Cancer.\nStudy
 : A Study of YL201 in Combination With Serplulimab in Participants With Tr
 eatment-naïve Extensive-stage Small Cell Lung Cancer\nEstimated primary c
 ompletion: June 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /tambotatug-pelitecan#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07739758
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06992609-1959@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Durvalumab: Phase 3 readout est. (NCT06992609)
DESCRIPTION:Durvalumab\, phase 3\, Small Cell Lung Cancer.\nStudy: Durvalum
 ab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.\nEstim
 ated primary completion: 30 June 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06992609
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07174583-1959@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT07174583)
DESCRIPTION:Durvalumab\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A Stud
 y of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell L
 ung Cancer\nEstimated primary completion: July 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07174583
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07559786-2166@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290717
DTEND;VALUE=DATE:20290718
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07559786)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Multi
 center\, Open-label\, Randomized\, Prospective Clinical Study of Adebrelim
 ab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC
 ) Without Progression After Concurrent Chemoradiotherapy\nEstimated primar
 y completion: 17 July 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/adebrelimab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07559786
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06287775-1959@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290725
DTEND;VALUE=DATE:20290726
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT06287775)
DESCRIPTION:Durvalumab\, phase 1/2\, Small Cell Lung Cancer.\nStudy: Testin
 g the Combination of an Anti-cancer Drug\, Iadademstat\, With Other Anti-c
 ancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small C
 ell Lung Cancer\nEstimated primary completion: 25 July 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06287775
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06287775-1962@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290725
DTEND;VALUE=DATE:20290726
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT06287775)
DESCRIPTION:Atezolizumab\, phase 1/2\, Small Cell Lung Cancer.\nStudy: Test
 ing the Combination of an Anti-cancer Drug\, Iadademstat\, With Other Anti
 -cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small
  Cell Lung Cancer\nEstimated primary completion: 25 July 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06287775
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07055581-1959@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07055581)
DESCRIPTION:Durvalumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Durvalum
 ab as Consolidation for Patients LS-SCLC\nEstimated primary completion: 31
  July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvaluma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 055581
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07459634-1959@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290804
DTEND;VALUE=DATE:20290805
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07459634)
DESCRIPTION:Durvalumab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Study 
 of Lurbinectedin in Combination With Durvalumab for the Treatment of Parti
 cipants With ES-SCLC\nEstimated primary completion: 4 August 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07459634
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07459634-2601@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290804
DTEND;VALUE=DATE:20290805
SUMMARY:Lurbinectedin: Phase 2 readout est. (NCT07459634)
DESCRIPTION:Lurbinectedin\, phase 2\, Small Cell Lung Cancer.\nStudy: A Stu
 dy of Lurbinectedin in Combination With Durvalumab for the Treatment of Pa
 rticipants With ES-SCLC\nEstimated primary completion: 4 August 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/lurbinectedin#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07459634
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06745323-2753@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290810
DTEND;VALUE=DATE:20290811
SUMMARY:Tarlatamab: Phase 2 readout est. (NCT06745323)
DESCRIPTION:Tarlatamab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Phase 
 2\, Open-label\, Randomized\, Multicenter Study of Tarlatamab Dosing Regim
 ens in Subjects With SCLC\nEstimated primary completion: 10 August 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/tarlatamab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06745323
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1959@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Durvalumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: QUIL
 T-3.055: A Study of Combination Immunotherapies in Patients Who Have Previ
 ously Received Treatment With Immune Checkpoint Inhibitors\nEstimated prim
 ary completion: 31 August 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1962@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: QU
 ILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Pre
 viously Received Treatment With Immune Checkpoint Inhibitors\nEstimated pr
 imary completion: 31 August 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07203053-2753@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Tarlatamab: Phase 2 readout est. (NCT07203053)
DESCRIPTION:Tarlatamab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Trial 
 of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung 
 Cancer (ES-SCLC) and ECOG PS 2\nEstimated primary completion: October 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/tarlatamab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07203053
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06801834-2601@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Lurbinectedin: Phase 3 readout est. (NCT06801834)
DESCRIPTION:Lurbinectedin\, phase 3\, Small Cell Lung Cancer.\nStudy: Study
  of Sacituzumab Govitecan Versus Standard of Care in Participants With Pre
 viously Treated Extensive Stage Small Cell Lung Cancer\nEstimated primary 
 completion: October 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/lurbinectedin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06801834
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05903092-1959@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05903092)
DESCRIPTION:Durvalumab\, phase 2\, Small Cell Lung Cancer.\nStudy: MOnaliZu
 mab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell
  Lung Cancer\nEstimated primary completion: 31 October 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05903092
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07502300-2010@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT07502300)
DESCRIPTION:Tislelizumab\, phase 3\, Small Cell Lung Cancer.\nStudy: A Stud
 y Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing
  Chemotherapy Combined With Tislelizumab as First-line Treatment in Patien
 ts With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)\nEstimated pr
 imary completion: December 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07502300
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07625644-1962@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT07625644)
DESCRIPTION:Atezolizumab\, phase 3\, Small Cell Lung Cancer.\nStudy: BL-M14
 D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Sma
 ll Cell Lung Cancer (BrenDeLL-Lung01)\nEstimated primary completion: Janua
 ry 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076
 25644
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06211036-2753@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300402
DTEND;VALUE=DATE:20300403
SUMMARY:Tarlatamab: Phase 3 readout est. (NCT06211036)
DESCRIPTION:Tarlatamab\, phase 3\, Small Cell Lung Cancer.\nStudy: Study Co
 mparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Ex
 tensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum\, Etopos
 ide and Durvalumab\nEstimated primary completion: 2 April 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/tarlatamab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06211036
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843940-1990@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300417
DTEND;VALUE=DATE:20300418
SUMMARY:Pumitamig: Phase 1/2 readout est. (NCT07843940)
DESCRIPTION:Pumitamig\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A Study
  to Test Obrixtamig in Combination With Pumitamig in People With Advanced 
 Small Cell Lung Cancer (Dareon®-Rosetta35)\nEstimated primary completion:
  17 April 2030. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pumit
 amig#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07843940
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843940-7739@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300417
DTEND;VALUE=DATE:20300418
SUMMARY:Obrixtamig: Phase 1/2 readout est. (NCT07843940)
DESCRIPTION:Obrixtamig\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A Stud
 y to Test Obrixtamig in Combination With Pumitamig in People With Advanced
  Small Cell Lung Cancer (Dareon®-Rosetta35)\nEstimated primary completion
 : 17 April 2030. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obri
 xtamig#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07843940
URL:https://assetmemo.bio/drug/obrixtamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06117774-2753@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300420
DTEND;VALUE=DATE:20300421
SUMMARY:Tarlatamab: Phase 3 readout est. (NCT06117774)
DESCRIPTION:Tarlatamab\, phase 3\, Small Cell Lung Cancer.\nStudy: Study Ev
 aluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lu
 ng Cancer (LS-SCLC)\nEstimated primary completion: 20 April 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/tarlatamab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06117774
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07707895-1962@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300426
DTEND;VALUE=DATE:20300427
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT07707895)
DESCRIPTION:Atezolizumab\, phase 1/2\, Small Cell Lung Cancer.\nStudy: DARE
 ON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People 
 With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers\nEsti
 mated primary completion: 26 April 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07707895
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07707895-7739@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300426
DTEND;VALUE=DATE:20300427
SUMMARY:Obrixtamig: Phase 1/2 readout est. (NCT07707895)
DESCRIPTION:Obrixtamig\, phase 1/2\, Small Cell Lung Cancer.\nStudy: DAREON
 ®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People Wi
 th Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers\nEstima
 ted primary completion: 26 April 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/obrixtamig#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07707895
URL:https://assetmemo.bio/drug/obrixtamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07242547-2753@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Tarlatamab: Phase 2 readout est. (NCT07242547)
DESCRIPTION:Tarlatamab\, phase 2\, Small Cell Lung Cancer.\nStudy: Study of
  Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited 
 Stage SCLC Patients\nEstimated primary completion: 1 June 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/tarlatamab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07242547
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07226999-2753@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300614
DTEND;VALUE=DATE:20300615
SUMMARY:Tarlatamab: Phase 2/3 readout est. (NCT07226999)
DESCRIPTION:Tarlatamab\, phase 2/3\, Small Cell Lung Cancer.\nStudy: Symbio
 tic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 
 in Combination With Chemotherapy and With Tarlatamab\, Alone or With Chemo
 therapy\, in Adult Participants With Extensive-Stage Small Cell Lung Cance
 r\nEstimated primary completion: 14 June 2030. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/tarlatamab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07226999
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07141771-2161@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Serplulimab: Phase 1/2 readout est. (NCT07141771)
DESCRIPTION:Serplulimab\, phase 1/2\, Small Cell Lung Cancer.\nStudy: An Um
 brella Study of Recurrent\, Extensive Stage Small Cell Lung Cancer Based o
 n Molecular Typing\nEstimated primary completion: 30 June 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/serplulimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07141771
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07141771-2601@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Lurbinectedin: Phase 1/2 readout est. (NCT07141771)
DESCRIPTION:Lurbinectedin\, phase 1/2\, Small Cell Lung Cancer.\nStudy: An 
 Umbrella Study of Recurrent\, Extensive Stage Small Cell Lung Cancer Based
  on Molecular Typing\nEstimated primary completion: 30 June 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/lurbinectedin#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07141771
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07365241-11131@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:ABBV-706: Phase 3 readout est. (NCT07365241)
DESCRIPTION:ABBV-706\, phase 3\, Small Cell Lung Cancer.\nStudy: A Study to
  Evaluate Adverse Events and Change in Disease Activity of Intravenous ABB
 V-706 Versus Standard of Care in Adult Participants With Relapsed/Refracto
 ry Small Cell Lung Cancer\nEstimated primary completion: September 2030. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/abbv-706#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07365241
URL:https://assetmemo.bio/drug/abbv-706#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227597-1962@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20301129
DTEND;VALUE=DATE:20301130
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT07227597)
DESCRIPTION:Atezolizumab\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A Cl
 inical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) i
 n People With Small Cell Lung Cancer (MK-6070-003)\nEstimated primary comp
 letion: 29 November 2030. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07227597
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227597-2527@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20301129
DTEND;VALUE=DATE:20301130
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT07227597)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2\, Small Cell Lung Cancer.\nSt
 udy: A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (M
 K-2400) in People With Small Cell Lung Cancer (MK-6070-003)\nEstimated pri
 mary completion: 29 November 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/ifinatamab-deruxtecan#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07227597
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227597-11236@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20301129
DTEND;VALUE=DATE:20301130
SUMMARY:Gocatamig: Phase 1/2 readout est. (NCT07227597)
DESCRIPTION:Gocatamig\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A Clini
 cal Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in P
 eople With Small Cell Lung Cancer (MK-6070-003)\nEstimated primary complet
 ion: 29 November 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/gocatamig#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07227597
URL:https://assetmemo.bio/drug/gocatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07947121-1962@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20310224
DTEND;VALUE=DATE:20310225
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT07947121)
DESCRIPTION:Atezolizumab\, phase 3\, Small Cell Lung Cancer.\nStudy: A Stud
 y of Risvutatug Rezetecan in Combination With Atezolizumab in Participants
  With Extensive Stage Small Cell Lung Cancer (EMBOLD-SCLC-303)\nEstimated 
 primary completion: 24 February 2031. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07947121
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07564401-11249@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20310303
DTEND;VALUE=DATE:20310304
SUMMARY:DJI136: Phase 1/2 readout est. (NCT07564401)
DESCRIPTION:DJI136\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A Study to
  Evaluate DJI136\, a DLL3-targeted CAR-T Therapy\nEstimated primary comple
 tion: 3 March 2031. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 ji136#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07564401
URL:https://assetmemo.bio/drug/dji136#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07699237-2753@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Tarlatamab: Phase 2 readout est. (NCT07699237)
DESCRIPTION:Tarlatamab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Multic
 enter Phase II Trial to Evaluate Rechallenge With Platinum-based Chemother
 apy (Carboplatin\, Etoposide) for Progression During Tarlatamab Therapy in
  Relapsed Extensive Disease Small-cell Lung Cancer (SCLC)\nEstimated prima
 ry completion: 30 June 2031. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/tarlatamab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07699237
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895056-1962@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07895056)
DESCRIPTION:Atezolizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Stud
 y to Assess Adverse Events and Change in Disease Activity of Intravenous (
 IV) ABBV-706 in Combination With Tarlatamab and Atezolizumab in Adult Part
 icipants With Extensive Stage-Small Cell Lung Cancer\nEstimated primary co
 mpletion: August 2031. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/atezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07895056
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895056-2753@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Tarlatamab: Phase 2 readout est. (NCT07895056)
DESCRIPTION:Tarlatamab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Study 
 to Assess Adverse Events and Change in Disease Activity of Intravenous (IV
 ) ABBV-706 in Combination With Tarlatamab and Atezolizumab in Adult Partic
 ipants With Extensive Stage-Small Cell Lung Cancer\nEstimated primary comp
 letion: August 2031. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 tarlatamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07895056
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895056-11131@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:ABBV-706: Phase 2 readout est. (NCT07895056)
DESCRIPTION:ABBV-706\, phase 2\, Small Cell Lung Cancer.\nStudy: A Study to
  Assess Adverse Events and Change in Disease Activity of Intravenous (IV) 
 ABBV-706 in Combination With Tarlatamab and Atezolizumab in Adult Particip
 ants With Extensive Stage-Small Cell Lung Cancer\nEstimated primary comple
 tion: August 2031. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ab
 bv-706#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07895056
URL:https://assetmemo.bio/drug/abbv-706#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895043-1962@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07895043)
DESCRIPTION:Atezolizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Stud
 y to Assess Adverse Events and Change in Disease Activity of Intravenous (
 IV) ABBV-706 in Combination With Alveltamig and Atezolizumab for Adults Pa
 rticipants With Extensive Stage-Small Cell Lung Cancer\nEstimated primary 
 completion: December 2031. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07895043
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895043-11131@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:ABBV-706: Phase 2 readout est. (NCT07895043)
DESCRIPTION:ABBV-706\, phase 2\, Small Cell Lung Cancer.\nStudy: A Study to
  Assess Adverse Events and Change in Disease Activity of Intravenous (IV) 
 ABBV-706 in Combination With Alveltamig and Atezolizumab for Adults Partic
 ipants With Extensive Stage-Small Cell Lung Cancer\nEstimated primary comp
 letion: December 2031. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/abbv-706#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07895043
URL:https://assetmemo.bio/drug/abbv-706#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07908537-11236@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20311208
DTEND;VALUE=DATE:20311209
SUMMARY:Gocatamig: Phase 3 readout est. (NCT07908537)
DESCRIPTION:Gocatamig\, phase 3\, Small Cell Lung Cancer.\nStudy: A Clinica
 l Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small 
 Cell Lung Cancer (MK-6070-004)\nEstimated primary completion: 8 December 2
 031. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/gocatamig#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07908537
URL:https://assetmemo.bio/drug/gocatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07637513-2753@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20371130
DTEND;VALUE=DATE:20371201
SUMMARY:Tarlatamab: Phase 3 readout est. (NCT07637513)
DESCRIPTION:Tarlatamab\, phase 3\, Small Cell Lung Cancer.\nStudy: Tarlatam
 ab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung C
 ancer\nEstimated primary completion: November 2037. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/tarlatamab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07637513
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
